Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal

(2018) James X. Sun et al.   PLoS Computational Biology

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors

(2018) Aaron M. Goodman et al.   JAMA Oncology

Correlation of tumor mutational burden and predicted functional impact of mutations across cancer types.

(2018) Jun Jia et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalized, molecularly matched combination therapies for treatment-na.

(2017) Jason K. Sicklick et al.   JOURNAL OF CLINICAL ONCOLOGY

Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit

(2017) Shumei Kato et al.   Journal of the National Comprehensive Cancer Network

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Rosai–Dorfman Disease with Activating KRAS Mutation — Response to Cobimetinib

(2017) Eric Jacobsen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dosing Three‐Drug Combinations That Include Targeted Anti‐Cancer Agents: Analysis of 37,763 Patients

(2017) Mina Nikanjam et al.   ONCOLOGIST

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

(2017) Christophe Massard et al.   Cancer Discovery

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

(2017) Zachary R. Chalmers et al.   Genome Medicine

Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns

(2017) Mina Nikanjam et al.   OncoImmunology

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study

(2016) Jennifer J. Wheler et al.   CANCER RESEARCH

Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013

(2016) Mina Nikanjam et al.   INTERNATIONAL JOURNAL OF CANCER

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience

(2016) M. Schwaederle et al.   MOLECULAR CANCER THERAPEUTICS

Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics

(2016) Teresa Helsten et al.   MOLECULAR CANCER THERAPEUTICS

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

(2016) J. J. Wheler et al.   MOLECULAR CANCER THERAPEUTICS

Perspective: The precision-oncology illusion

(2016) Vinay Prasad   NATURE

Analysis of protein-coding genetic variation in 60,706 humans

(2016) Monkol Lek et al.   NATURE

Prognostic and Predictive Value inKRASin Non–Small-Cell Lung Cancer

(2016) Kevin Wood et al.   JAMA Oncology

TP53 mutational status is predictive of pazopanib response in advanced sarcomas

(2015) K. Koehler et al.   ANNALS OF ONCOLOGY

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy

(2015) M. Schwaederle et al.   CANCER RESEARCH

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics

(2015) Shumei Kato et al.   CELL CYCLE

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

(2015) Christophe Le Tourneau et al.   LANCET ONCOLOGY

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center

(2015) Barbara A. Parker et al.   Journal of Oncology Practice

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy

(2015) Rabih Said et al.   Oncotarget

Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations

(2014) J. Wheler et al.   CANCER RESEARCH

Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin

(2014) Katherine A. Hoadley et al.   CELL

Molecular Tumor Board: The University of California San Diego Moores Cancer Center Experience

(2014) M. Schwaederle et al.   ONCOLOGIST

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Emerging landscape of oncogenic signatures across human cancers

(2013) Giovanni Ciriello et al.   NATURE GENETICS

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

(2012) A.-M. Tsimberidou et al.   CLINICAL CANCER RESEARCH

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

(2010) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Alternate Endpoints for Screening Phase II Studies

(2009) N. Dhani et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER